| Michael Schmitt, | |
|
6245 Inkster Rd, Garden City, MI 48135-4001 | |
| (734) 458-4486 | |
| Not Available |
| Full Name | Michael Schmitt |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 12 Years |
| Location | 6245 Inkster Rd, Garden City, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376958363 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 5101021155 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Health | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| 24 On Physicians Of Sc Llc | 5890127344 | 98 |
| Apogee Medical Group South Carolina | 8921193020 | 43 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
| Entity Name | Apogee Medical Group South Carolina |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619028545 PECOS PAC ID: 8921193020 Enrollment ID: O20071004000474 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
| Entity Name | Cogent Healthcare Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609827823 PECOS PAC ID: 2961483607 Enrollment ID: O20151015001850 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
| Entity Name | Southeastern Hospitalist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003280108 PECOS PAC ID: 3476855420 Enrollment ID: O20160125000378 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
| Entity Name | 24 On Physicians Of Sc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144877655 PECOS PAC ID: 5890127344 Enrollment ID: O20191121001203 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Schmitt, 6245 Inkster Rd, Garden City, MI 48135-4001 Ph: (734) 458-4486 | Michael Schmitt, 6245 Inkster Rd, Garden City, MI 48135-4001 Ph: (734) 458-4486 |
News Archive
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.
Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat.
› Verified 8 days ago
Dr. Bojan Jokic, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 Fax: 734-458-4496 | |
Dr. Hassan Khan, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Dr. Suryakumari Guthikonda, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 30260 Cherry Hill Rd, Suite A, Garden City, MI 48135 Phone: 734-466-9000 Fax: 734-466-9700 | |
Dr. Adam Edward Chornoby, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 30626 Ford Rd, Garden City, MI 48135 Phone: 734-261-9211 Fax: 734-261-8537 | |
Dr. Rakesh Reddy Devireddy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Dr. Yaser T Dawod, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6255 Inkster Rd Ste 307, Garden City, MI 48135 Phone: 734-525-0319 Fax: 734-525-7227 | |
Dr. Kirsten Waarala, D.O. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 |